Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Hodgkin Disease 2Hematologic Neoplasms 2Sezary Syndrome 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Cytomegalovirus Infections 1

Interventions

Peripheral Blood Stem Cell Transplantation 36fludarabine phosphate 32Cyclophosphamide 30Mycophenolic Acid 26Whole-Body Irradiation 23Tacrolimus 22Cyclosporine 20Busulfan 16Antilymphocyte Serum 16Methotrexate 14Radiotherapy 13Filgrastim 12Flow Cytometry 11Etoposide 11Methylprednisolone 8Melphalan 8Therapeutics 7Rituximab 7Lenalidomide 7Psychiatric Rehabilitation 6Cord Blood Stem Cell Transplantation 6Bortezomib 6Transplantation 5Sirolimus 5Polymerase Chain Reaction 5Gemcitabine 5Everolimus 5Brentuximab Vedotin 5Alemtuzumab 5pembrolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sezary Syndrome × letermovir × Clear all
NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
6 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡